144 related articles for article (PubMed ID: 29331774)
1. The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia.
Zhao H; Zhu H; Huang J; Zhu Y; Hong M; Zhu H; Zhang J; Li S; Yang L; Lian Y; Wang S; Mao J; Chen Y; Li J; Qian S
Leuk Res; 2018 Mar; 66():1-7. PubMed ID: 29331774
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults.
Yoo KH; Cho J; Han B; Kim SH; Shin DY; Hong J; Kim H; Kim HJ; Zang DY; Yoon SS; Jin JY; Lee JH; Hong DS; Park SK
PLoS One; 2020; 15(8):e0235503. PubMed ID: 32760083
[TBL] [Abstract][Full Text] [Related]
3. Next-generation sequencing reveals relapse and leukemia-free survival risks in newly diagnosed acute myeloid leukemia treated with CAG regimen combined with decitabine.
Huang S; Chen P; Wang L; Xu L; Wang N; Li F; Dou L; Liu D
Cancer Pathog Ther; 2024 Apr; 2(2):112-120. PubMed ID: 38601484
[TBL] [Abstract][Full Text] [Related]
4. Low-dose decitabine for previously untreated acute myeloid leukemia ineligible for intensive chemotherapy aged 65 years or older: a prospective study based on comprehensive geriatric assessment.
Feng R; Zhang S; Li JT; Wang T; Zhang CL; Bai JF; Yang L; Wang LR; Jing HM; Liu H
Ther Adv Hematol; 2023; 14():20406207231208979. PubMed ID: 38033755
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human thrombopoietin promotes platelet recovery in DCAG-treated patients with intermediate-high-risk MDS/hypoproliferative AML.
Chen X; Wang Y; Zang Y; Wei Z; Zhang W; Wei X; Luo G; Chen L; Zhang Y; Xu Z
Medicine (Baltimore); 2023 Mar; 102(13):e33373. PubMed ID: 37000082
[TBL] [Abstract][Full Text] [Related]
6. The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine.
Li Y; Mao X; Li M; Li L; Tong X; Huang L
Clin Epigenetics; 2024 Jan; 16(1):16. PubMed ID: 38254153
[TBL] [Abstract][Full Text] [Related]
7. The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia.
Briski R; Garcia-Manero G; Kantarjian H; Ravandi F
Ther Adv Hematol; 2023; 14():20406207231205429. PubMed ID: 37854355
[TBL] [Abstract][Full Text] [Related]
8. Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort.
Premnath N; Chung SS; Weinberg OK; Ikpefan R; Pandey M; Kaur G; Geethakumari PR; Afrough A; Awan FT; Anderson LD; Vusirikala M; Collins RH; Chen W; Agathocleous M; Madanat YF
Leuk Res; 2023 Feb; 125():107001. PubMed ID: 36566538
[TBL] [Abstract][Full Text] [Related]
9. Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy.
Young CS; Clarke KM; Kettyle LM; Thompson A; Mills KI
Oncotarget; 2017 Aug; 8(31):51429-51446. PubMed ID: 28881658
[TBL] [Abstract][Full Text] [Related]
10. Tet2 is a tumor suppressor in the pre-leukemic phase of T-cell acute lymphoblastic leukemia.
De Coninck S; Roels J; Lintermans B; T'Sas S; Taghon T; Curtis DJ; Pieters T; Goossens S; Van Vlierberghe P
Blood Adv; 2024 Mar; ():. PubMed ID: 38536906
[TBL] [Abstract][Full Text] [Related]
11. Tet2 promotes pathogen infection-induced myelopoiesis through mRNA oxidation.
Shen Q; Zhang Q; Shi Y; Shi Q; Jiang Y; Gu Y; Li Z; Li X; Zhao K; Wang C; Li N; Cao X
Nature; 2018 Feb; 554(7690):123-127. PubMed ID: 29364877
[TBL] [Abstract][Full Text] [Related]
12. Tracking hematopoietic precursor division ex vivo in real time.
Wang Y; Tian H; Cai W; Lian Z; Bhavanasi D; Wu C; Sato T; Kurokawa M; Wu D; Fu L; Wang H; Shen H; Liang D; Huang J
Stem Cell Res Ther; 2018 Jan; 9(1):16. PubMed ID: 29361987
[TBL] [Abstract][Full Text] [Related]
13. SETDB1 prevents TET2-dependent activation of IAP retroelements in naïve embryonic stem cells.
Deniz Ö; de la Rica L; Cheng KCL; Spensberger D; Branco MR
Genome Biol; 2018 Jan; 19(1):6. PubMed ID: 29351814
[TBL] [Abstract][Full Text] [Related]
14. Cellular toxicity driven by high-dose vitamin C on normal and cancer stem cells.
Kim TJ; Byun JS; Kwon HS; Kim DY
Biochem Biophys Res Commun; 2018 Feb; 497(1):347-353. PubMed ID: 29432735
[TBL] [Abstract][Full Text] [Related]
15. Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy.
Castelli G; Pelosi E; Testa U
Onco Targets Ther; 2018; 11():131-155. PubMed ID: 29343972
[TBL] [Abstract][Full Text] [Related]
16. A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium.
Sun W; Triche T; Malvar J; Gaynon P; Sposto R; Yang X; Bittencourt H; Place AE; Messinger Y; Fraser C; Dalla-Pozza L; Salhia B; Jones P; Wayne AS; Gore L; Cooper TM; Liang G
Blood; 2018 Mar; 131(10):1145-1148. PubMed ID: 29339403
[No Abstract] [Full Text] [Related]
17. Treatment of pancreatic cancer with intravenous vitamin C: a case report.
Drisko JA; Serrano OK; Spruce LR; Chen Q; Levine M
Anticancer Drugs; 2018 Apr; 29(4):373-379. PubMed ID: 29438178
[TBL] [Abstract][Full Text] [Related]
18. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
19. Influence of Vitamin C on Lymphocytes: An Overview.
van Gorkom GNY; Klein Wolterink RGJ; Van Elssen CHMJ; Wieten L; Germeraad WTV; Bos GMJ
Antioxidants (Basel); 2018 Mar; 7(3):. PubMed ID: 29534432
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
